In a B16 melanoma model, mice were treated with anti-CTLA-4 antibody and vaccinated with irradiated B16 tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor (the vaccine is usually referred to as “GVAX”) 77. This evidence concerns the gene CTLA4 and neoplasm.